Capital Investment Advisory Services LLC lessened its holdings in Edwards Lifesciences Corp (NYSE:EW) by 68.7% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 455 shares of the medical research company’s stock after selling 1,000 shares during the quarter. Capital Investment Advisory Services LLC’s holdings in Edwards Lifesciences were worth $87,000 as of its most recent SEC filing.
Several other institutional investors have also modified their holdings of EW. Pinnacle Bank purchased a new stake in shares of Edwards Lifesciences during the fourth quarter worth $65,000. Mackay Shields LLC increased its stake in shares of Edwards Lifesciences by 58.8% in the fourth quarter. Mackay Shields LLC now owns 53,020 shares of the medical research company’s stock worth $8,121,000 after purchasing an additional 19,624 shares during the period. Gateway Investment Advisers LLC increased its stake in shares of Edwards Lifesciences by 1,161.8% in the fourth quarter. Gateway Investment Advisers LLC now owns 121,640 shares of the medical research company’s stock worth $18,632,000 after purchasing an additional 112,000 shares during the period. Cetera Advisor Networks LLC increased its stake in shares of Edwards Lifesciences by 3.8% in the fourth quarter. Cetera Advisor Networks LLC now owns 1,573 shares of the medical research company’s stock worth $242,000 after purchasing an additional 57 shares during the period. Finally, Mercer Global Advisors Inc. ADV bought a new position in shares of Edwards Lifesciences in the first quarter worth about $843,000. 84.89% of the stock is owned by institutional investors and hedge funds.
In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,500 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, February 13th. The stock was sold at an average price of $177.75, for a total transaction of $977,625.00. Following the sale, the vice president now directly owns 24,482 shares of the company’s stock, valued at $4,351,675.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael A. Mussallem sold 32,800 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, February 12th. The shares were sold at an average price of $176.90, for a total value of $5,802,320.00. Following the sale, the chief executive officer now directly owns 75,926 shares in the company, valued at $13,431,309.40. The disclosure for this sale can be found here. Insiders have sold 114,328 shares of company stock worth $20,121,304 over the last ninety days. Company insiders own 1.63% of the company’s stock.
Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, April 23rd. The medical research company reported $1.32 earnings per share for the quarter, beating analysts’ consensus estimates of $1.23 by $0.09. The company had revenue of $993.00 million for the quarter, compared to the consensus estimate of $989.87 million. Edwards Lifesciences had a return on equity of 31.71% and a net margin of 20.03%. The company’s quarterly revenue was up 11.0% on a year-over-year basis. During the same period in the previous year, the business earned $1.22 earnings per share. On average, sell-side analysts predict that Edwards Lifesciences Corp will post 5.22 EPS for the current year.
A number of equities analysts have recently commented on the company. Zacks Investment Research upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $203.00 price objective on the stock in a research note on Thursday. Stifel Nicolaus lifted their price objective on Edwards Lifesciences from $190.00 to $200.00 and gave the stock a “buy” rating in a research note on Wednesday. Deutsche Bank lifted their price objective on Edwards Lifesciences from $164.00 to $184.00 and gave the stock a “hold” rating in a research note on Wednesday. Jefferies Financial Group lifted their target price on Edwards Lifesciences from $195.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Raymond James decreased their target price on Edwards Lifesciences from $210.00 to $200.00 and set an “outperform” rating on the stock in a research report on Wednesday. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and fourteen have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $187.19.
ILLEGAL ACTIVITY WARNING: “Edwards Lifesciences Corp (EW) Stake Lowered by Capital Investment Advisory Services LLC” was originally posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.baseballdailydigest.com/news/2019/04/26/edwards-lifesciences-corp-ew-stake-lowered-by-capital-investment-advisory-services-llc.html.
Edwards Lifesciences Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
Further Reading: What does RSI mean?
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.